207 related articles for article (PubMed ID: 21913401)
1. [Target-specific screening of antivirulence preparations for chronic infection therapy].
Zigangirova NA; Gintsburg AL
Zh Mikrobiol Epidemiol Immunobiol; 2011; (4):107-15. PubMed ID: 21913401
[TBL] [Abstract][Full Text] [Related]
2. Specific Antivirulence Activity, A New Concept for Reliable Screening of Virulence Inhibitors.
Defoirdt T
Trends Biotechnol; 2016 Jul; 34(7):527-529. PubMed ID: 26879186
[TBL] [Abstract][Full Text] [Related]
3. Novel agents to inhibit microbial virulence and pathogenicity.
Escaich S
Expert Opin Ther Pat; 2010 Oct; 20(10):1401-18. PubMed ID: 20718591
[TBL] [Abstract][Full Text] [Related]
4. The biology and future prospects of antivirulence therapies.
Cegelski L; Marshall GR; Eldridge GR; Hultgren SJ
Nat Rev Microbiol; 2008 Jan; 6(1):17-27. PubMed ID: 18079741
[TBL] [Abstract][Full Text] [Related]
5. Important Complexities of the Antivirulence Target Paradigm: A Novel Ostensibly Resistance-Avoiding Approach for Treating Infections.
Russo TA; Spellberg B; Johnson JR
J Infect Dis; 2016 Mar; 213(6):901-3. PubMed ID: 26563238
[TBL] [Abstract][Full Text] [Related]
6. Global priority pathogens: virulence, antimicrobial resistance and prospective treatment options.
M Campos JC; Antunes LC; Ferreira RB
Future Microbiol; 2020 May; 15():649-677. PubMed ID: 32495702
[No Abstract] [Full Text] [Related]
7. Recent Advances in Anti-virulence Therapeutic Strategies With a Focus on Dismantling Bacterial Membrane Microdomains, Toxin Neutralization, Quorum-Sensing Interference and Biofilm Inhibition.
Fleitas Martínez O; Cardoso MH; Ribeiro SM; Franco OL
Front Cell Infect Microbiol; 2019; 9():74. PubMed ID: 31001485
[TBL] [Abstract][Full Text] [Related]
8. Possible drugs for the treatment of bacterial infections in the future: anti-virulence drugs.
Ogawara H
J Antibiot (Tokyo); 2021 Jan; 74(1):24-41. PubMed ID: 32647212
[TBL] [Abstract][Full Text] [Related]
9. [Type III bacterial secretion system, a promising target for the development of a new generation of antibiotic drugs].
Gintsburg AL; Zigangirova NA; Zorina VV
Vestn Ross Akad Med Nauk; 2008; (10):34-9. PubMed ID: 19140396
[TBL] [Abstract][Full Text] [Related]
10. Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance.
Dickey SW; Cheung GYC; Otto M
Nat Rev Drug Discov; 2017 Jul; 16(7):457-471. PubMed ID: 28337021
[TBL] [Abstract][Full Text] [Related]
11. [The search for novel antibiotics--strategies and current approaches].
Schmid P
Berl Munch Tierarztl Wochenschr; 2014; 127(11-12):498-512. PubMed ID: 25872259
[TBL] [Abstract][Full Text] [Related]
12. Virulence-targeted Antibacterials: Concept, Promise, and Susceptibility to Resistance Mechanisms.
Ruer S; Pinotsis N; Steadman D; Waksman G; Remaut H
Chem Biol Drug Des; 2015 Oct; 86(4):379-99. PubMed ID: 25589217
[TBL] [Abstract][Full Text] [Related]
13. Candidate targets for new antivirulence drugs: selected cases of bacterial adhesion and biofilm formation.
Klemm P; Hancock V; Kvist M; Schembri MA
Future Microbiol; 2007 Dec; 2(6):643-53. PubMed ID: 18041905
[TBL] [Abstract][Full Text] [Related]
14. Plant Natural Products Targeting Bacterial Virulence Factors.
Silva LN; Zimmer KR; Macedo AJ; Trentin DS
Chem Rev; 2016 Aug; 116(16):9162-236. PubMed ID: 27437994
[TBL] [Abstract][Full Text] [Related]
15. Antivirulence as a new antibacterial approach for chemotherapy.
Escaich S
Curr Opin Chem Biol; 2008 Aug; 12(4):400-8. PubMed ID: 18639647
[TBL] [Abstract][Full Text] [Related]
16. Nature's clarion call of antibacterial resistance: are we listening?
Theuretzbacher U; Toney JH
Curr Opin Investig Drugs; 2006 Feb; 7(2):158-66. PubMed ID: 16499286
[TBL] [Abstract][Full Text] [Related]
17. [Target-directed search of anti-virulence drugs].
Zigangirova NA; Fedina ED; Zorina VV; Bortsov PA; Tokarskaia EA; Kariagina AS; Alekseevskiĭ AV; Kraiushkin MM; Zaiakin ES; Iarovenko VN; Gintsburg AL
Zh Mikrobiol Epidemiol Immunobiol; 2009; (4):71-7. PubMed ID: 19715208
[TBL] [Abstract][Full Text] [Related]
18. Alternative strategies for the application of aminoglycoside antibiotics against the biofilm-forming human pathogenic bacteria.
Khan F; Pham DTN; Kim YM
Appl Microbiol Biotechnol; 2020 Mar; 104(5):1955-1976. PubMed ID: 31970432
[TBL] [Abstract][Full Text] [Related]
19. Quorum Sensing Inhibition by Marine Bacteria.
Borges A; Simões M
Mar Drugs; 2019 Jul; 17(7):. PubMed ID: 31340463
[TBL] [Abstract][Full Text] [Related]
20. Quorum Sensing as Antivirulence Target in Cystic Fibrosis Pathogens.
Scoffone VC; Trespidi G; Chiarelli LR; Barbieri G; Buroni S
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
